RecruitingPhase 3NCT06660693
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis: an Open-label Randomized Controlled Trial (RESCUE-UC).
Sponsor
McMaster University
Enrollment
134 participants
Start Date
Apr 16, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is non-inferior to conventional management with infliximab only.
Eligibility
Min Age: 18 YearsMax Age: 64 Years
Inclusion Criteria5
- Confirmed diagnosis of UC, based on conventional clinical, endoscopic, and/or histologic criteria
- Admitted to hospital with acute severe flare and refractory to three days of intravenous steroids (at minimum of 40mg methylprednisolone, or equivalent, daily). Refractory is defined using the Oxford criteria at day 3 of steroid therapy: presence of \> 8 stools/day or CRP \> 45 mg/L
- Will undergo or has already undergone a baseline colonoscopy or flexible sigmoidoscopy while in hospital or in the 4 weeks preceding trial entry, with a baseline MES ≥2 based on locally evaluated endoscopy
- Provided written informed consent
- Subject is willing and able to adhere to study procedures, and describe in the procedures that screening and safety monitoring procedures will be applied as per upadacitinib and infliximab Canadian product monographs
Exclusion Criteria17
- Contraindications to receiving either infliximab or upadacitinib (as per current Canadian product monograph)
- Previously used infliximab or a JAK inhibitor for UC
- Patients \> 65 years of age
- Pregnant or breastfeeding
- Women of reproductive potential who are unwilling to agree to using effective contraception during treatment and 4 weeks following the final dose of upadacitinib
- Concurrent Clostridium difficile, other gastrointestinal infection, or other active systemic or localized infection which would preclude treatment with systemically acting biologic or small molecule therapy
- Patients with symptoms of thrombosis, or confirmed venous or arterial thromboembolism
- Active TB (patients should be tested for TB prior to upadacitinib or infliximab treatment)
- HBV/HCV positive
- Untreated malignancy or ongoing treatment for malignancy
- Concomitant treatment with strong CYP3A4 inhibitors or inducers
- Severe hepatic impairment
- Severe renal impairment (CrCl \< 30 ml/min)
- Patients who have received live vaccines in the 28 days prior to study entry.
- Patients with moderate or severe (NYHA Class III/IV) congestive heart failure.
- Patients with a history of hypersensitivity to infliximab, to other murine proteins, or to any of the excipients.
- Patients who are hypersensitive to upadacitinib or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Interventions
DRUGUpadacitinib Oral Product
Upadacitinib oral 45mg once daily.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06660693
Related Trials
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT073023601 location
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
NCT043721081 location
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT0666333230 locations
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
NCT071023681 location
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
NCT072422481 location